Pirtobrutinib for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma after 1 or more BTK inhibitors [ID6269]
In development
Reference number: GID-TA11298
Expected publication date: TBC
Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during mid-April 2025 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately late June 2025.